Treatment of resistant hypertension is a priority because patients with nonoptimal blood pressure are at high risk for major cardiovascular events. Pharmacological advances include the use of aldosterone antagonists and the development of several new strategies. Device-based therapies such as catheter-based renal denervation and electrical stimulation of baroreceptors are showing promising results.
|Number of pages||8|
|Publication status||Published - Jan 2013|